51834 Federal Register / Vol. 71, No. 169 / Thursday, August 31, 2006 / Notices 

TABLE A.—ANNUALIZED BURDEN ESTIMATES FOR CHIS 2007 DATA COLLECTION

Data collection 

Estimated 

number of 

respondents 

Frequency of 

response 

Average time 

per response 

Annual hour 

burden 

(1) Pilot Test Adult Demographics ................................................................. 150 1 .07 11 

CCM ............................................................................................................... 150 1 .03 5 

(2) Full Survey Adult Demographics .............................................................. 55,000 1 .07 3,850 

CCM ............................................................................................................... 55,000 1 .03 1,650 

Totals ...................................................................................................... 55,150 1 .1 5,516 

There are no Capital Costs to report. There are no Operating or Maintenance Costs to report. 

Request for Comments: Written 

comments and/or suggestions from the 

public and affected agencies are invited 

on one or more of the following points: 

(1) Whether the proposed collection of 

information is necessary for the 

proposed performance of the functions 

of the agency, including whether the 

information shall have practical utility; 

(2) The accuracy of the agency’s 

estimate of the burden of the proposed 

collection of information including the 

validity of the methodology and 

assumptions used; (3) Ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) 

Ways to minimize the burden of the 

collection of information on those who 

are to respond, including the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the data collection plans and 

instruments, contact Nancy Breen, 

Ph.D., Project Officer, National Cancer 

Institute, EPN 4005, 6130 Executive 

Boulevard MSC 7344, Bethesda, 

Maryland 20852–7344, or call non-toll 

free number 301–496–8500 or FAX your 

request, including your address to 

breenn@mail.nih.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 60 days of this 

publication. 

Dated: August 24, 2006. 

Rachelle Ragland-Greene, 

NCI Project Clearance Liaison, National 

Institutes of Health. 

[FR Doc. 06–7328 Filed 8–30–06; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of federally 

funded research and development. 

Foreign patent applications are filed on 

selected inventions to extend market 

coverage for companies and may also be 

available for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Novel Acylthiol Compositions and 

Methods of Making and Using Them 

Description of Technology: This 

invention provides a novel family of 

acylthiols and uses thereof. More 

specifically, this invention provides 

effective inhibitors of HIV that 

selectively target its highly conserved 

nucleocapsid protein (NCp7) by 

interacting with metal chelating 

structures of a zinc finger-containing 

protein. Because of the mutationally 

intolerant nature of NCp7, drug 

resistance is much less likely to occur 

with compounds attacking this target. In 

addition, these drugs should inactivate 

all types and strains of HIV and could 

also inactivate other retroviruses, since 

most retroviruses share one or two 

highly conserved zinc fingers that have 

the CCHC motif of the HIV Ncp7. 

Finally, this invention could be very 

useful for the large-scale practical 

synthesis of HIV inhibitors, because 

these compounds can be prepared by 

using inexpensive starting materials and 

facile reactions. Thus, it opens the 

possibility that an effective drug 

treatment for HIV could be made 

available to much larger populations. 

These thioesters may also be used as an 

active component in topical 

applications that serve as a barrier to 

HIV infection. 

Inventors: John K. Inman (NIAID), 

Atul Goel (NCI), Ettore Appella (NCI), 

James A. Turpin (NIAID), Marco Schito 

(NCI). 

Publications: 

1. ML Schito, A Goel, Y Song, JK 

Inman, RJ Fattah, WG Rice, JA Turpin, 

A Sher, E Appella. In vitro antiviral 

activity of novel human 

immunodeficiency virus type 1 

nucleocapsid p7 zinc finger inhibitors 

in a transgenic murine model. AIDS Res 

Hum Retroviruses. 2003 Feb;19(2):91–

101. 

2. P Srivastava, M Schito, RJ Fattah, 

T Hara, T Hartman, RW Buckheit Jr, JA 

Turpin, JK Inman, E Appella. 

Optimization of unique, uncharged 

thioesters as inhibitors of HIV 

replication. Bioorg Med Chem. 2004 Dec 

15;12(24):6437–6450. 

3. LM Jenkins, JC Byrd, T Hara, P 

Srivastava, SJ Mazu, SJ Stahl, JK Inman, 

E Appella, JG Omichinski, P Legault. 

Studies on the mechanism of 

inactivation of the HIV–1 nucleocapsid 

protein NCp7 with 2- 

mercaptobenzamide thioesters. J Med 

Chem. 2005 Apr 21;48(8):2847–2858. 

4. V Basrur, Y Song, SJ Mazur, Y 

Higashimoto, JA Turpin, WG Rice, JK 

Inman, E Appella. Inactivation of HIV–

1 nucleocapsid protein P7 by 

pyridinioalkanoyl thioesters. 

Characterization of reaction products 

and proposed mechanism of action. J 

Biol Chem. 2000 May 19;275(20):14890–

14897. 

5. JA Turpin, Y Song, JK Inman, M 

Huang, A Wallqvist, A Maynard, DG 


erjones on PROD1PC72 with NOTICES
Federal Register / Vol. 71, No. 169 / Thursday, August 31, 2006 / Notices 51835 

Covell, WG Rice, E Appella. Synthesis 

and biological properties of novel 

pyridinioalkanoyl thiolesters (PATE) as 

anti-HIV–1 agents that target the viral 

nucleocapsid protein zinc fingers. J Med 

Chem. 1999 Jan 14;42(1):67–86. 

Patent Status: U.S. Patent Application 

No. 10/485,165 filed 28 Jan 2004, 

claiming priority to 03 Aug 2001 (HHS 

Reference No. E–329–2000/0–US–06). 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contact: Sally H. Hu, Ph.D., 

M.B.A.; 301/435–5605; 

hus@mail.nih.gov. 

Novel Thioesters and Uses Thereof 

Description of Technology: The 

human immunodeficiency virus (HIV) is 

the causative agent of acquired 

immunodeficiency syndrome (AIDS). 

Drug-resistance is a critical factor 

contributing to the gradual loss of 

clinical benefit to treatments for HIV 

infection. Accordingly, combination 

therapies have further evolved to 

address the mutating resistance of HIV. 

However, there has been great concern 

regarding the apparent growing 

resistance of HIV strains to current 

therapies. 

The present invention provides for a 

novel family of thioesters and uses 

thereof. These thioesters are capable of 

inactivating viruses by a variety of 

mechanisms, particularly by 

complexing with metal ion-complexing 

zinc fingers. The invention further 

provides for methods for inactivating a 

virus, such as the human 

immunodeficiency virus (HIV), using 

these compounds, and thereby also 

inhibiting transmission of the virus. 

Inventors: James A. Turpin (NCI), 

Yongsheng Song (NCI), John K. Inman 

(NIAID), Mingjun Huang (NCI), Anders 

Wallqvist (NCI), David G. Covell (NCI), 

William G. Rice (NCI), Ettore Appella 

(NCI), et al. 

Patent Status: U.S. Patent No. 

6,706,729 issued 16 Mar 2004 (HHS 

Reference No. E–136–1998/0–US–10); 

U.S. Patent Application No. 10/738,062 

filed 16 Dec 2003 (HHS Reference No. 

E–136–1998/0–US–11). 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contact: Sally H. Hu, Ph.D., 

M.B.A.; 301/435–5605; 

hus@mail.nih.gov. 

Dated: August 25, 2006. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 06–7327 Filed 8–30–06; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

A Novel Small Protein Antibiotic 

Description of Technology: Due to the 

increase in drug resistance among 

bacteria, continued progress in the 

development of new antibiotic 

treatments is needed. Available for 

licensing and commercial development 

is the small protein SrgT, its analogs 

and related peptides. SrgT is a 43 amino 

acid protein that effectively inhibits 

bacterial growth. This protein likely 

exerts its antibiotic action by inhibiting 

the metabolism of glucose in these 

microorganisms. The claimed invention 

includes methods for SrgT synthesis 

and suggested modifications for 

production of SrgT analogs and related 

peptides, which may remain effective 

against potential SrgT resistant bacteria. 

Thus, the current technology provides a 

novel approach to the treatment and 

prevention of bacterial infections. 

Application: Novel therapeutics and 

prophylactics for bacterial infections. 

Development Status: Preclinical data 

is available at this time. 

Inventors: Carin K. Vanderpool and 

Susan Gottesman (NCI). 

Selected Publication: CK Vanderpool, 

S Gottesman. Involvement of a novel 

transcriptional activator and small RNA 

in post-transcriptional regulation of the 

glucose phosphoenolpyruvate 

phosphotransferase system. Mol 

Microbiol. 2004 Nov; 54(4):1076–1089. 

Patent Status: U.S. Provisional 

Application No. 60/799,830 filed 11 

May 2006 (HHS Reference No. E–166–

2006/0–US–01). 

Licensing Status: Available for nonexclusive and exclusive licensing. 

Licensing Contact: Cristina 

Thalhammer-Reyero, Ph.D., M.B.A.; 

301/435–4507; thalhamc@mail.nih.gov. 

Methods and Compositions for the 

Production of Highly Effective Vaccines 

Against Cancers and Infections 

Diseases 

Description of Technology: Because 

cancers and infectious diseases remain 

prominent causes of death among adults 

and children worldwide, the availability 

of vaccines targeting these conditions is 

a global health priority. With the current 

vaccine development state-of-the-art, 

there are limitless combinations of 

enhancing molecules that can be used 

with antigen vaccines targeting these 

diseases. The technology offered for 

licensing and commercial development 

combines effective aspects of antigenvaccines, including peptides and other 

forms of vaccination, with enhancing 

molecules, including co-stimulation of 

T cell immunity for efficient vaccine 

development. 

The claimed invention includes a 

non-viral polynucleotide vector 

encoding immune enhancing molecules, 

such as the T cell co-stimulatory 

molecule B7.1 (CD80), which 

significantly enhance cellular immune 

responses when combined with antigen 

stimulation. Delivery of this costimulatory molecule as non-replicating 

DNA with any antigenic form, peptides 

in this case, overcomes the problems of 

combining enhancing molecules with 

the antigen in the same DNA vector, coinfecting or transfecting these molecules 

in the same antigen presenting or tumor 

cell, or manufacturing enhancing 

molecules in the same format as the 

antigens. Furthermore, the use of this 

chimeric vaccine with the enhancing 

molecule expressed as polynucleotide 

vector overcomes the low antigenicity 

and safety considerations of viral 

vectors, as well as the instability and 

conformational maintenance challenges 

associated with the use of full-length 

protein delivery. Furthermore, 

polynucleotide’s constructs encoding 

enhancing molecules are inexpensive to 

produce and can potentially be used 

along with any form of antigen vaccine 

delivery system, including peptides, 

full-length proteins and naked DNA 

antigens. 


erjones on PROD1PC72 with NOTICES